Cefetamet in the treatment of acute sinusitis in adult patients.
Cefetamet, an oral third-generation cephalosporin, was investigated in a prospective, randomized, open, comparative trial in 41 outpatients with acute sinusitis. The efficacy of 500 mg cefetamet given orally twice daily for 7 days to 22 patients was compared with that of 500 mg cefaclor given orally three times daily for 7 days to 19 patients. Sinus punctures were performed before antimicrobial therapy in 10 patients from each treatment group. A successful bacteriological response was obtained in all the 21 assessable patients treated with cefetamet and in the cefaclor-treated group 18 assessable patients were cured and two were improved, but one failed to respond to therapy. The tolerability of both drugs was good and no withdrawals from treatment were necessary.
Clinical Research, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
U
U
Gauger
P
P
Inoka
G
G
Germano
M
M
Kissling
D000208:Acute Disease; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy; D002433:Cefaclor / Q000627:therapeutic use; D015296:Ceftizoxime / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012852:Sinusitis / Q000188:drug therapy* / Q000503:physiopathology
C047444:cefetamet; D002433:Cefaclor; D015296:Ceftizoxime